Indivior
在场
Indivior 的所有者是 Reckitt Benckiser.
是其中之一......
Reckitt Benckiser 是一家在股票代码 RB (GB) 下上市的公司。
Reckitt Benckiser 在 10 个国家有直接业务。Reckitt Benckiser 拥有 12家子公司，其中包括 Indivior、Reckitt Benckiser ANZ 和 Reckitt Benckiser Arabia。
他们在：
高管
查看带有其 28 名主要高管的组织结构图
Indivior 搜索最多的简介
- Mark Crossley, Chief Executive Officer and Director
- Peter Bains, Non-Executive Director
- Graham Hetherington, Chairman of the Board (retiring on Dec 31 202...
高管在Indivior变化
- Jerome Lande, Non-Executive Director, 将于 202412月31 退休 (新闻发布的2024十一月18号).
- Graham Hetherington, Chairman of the Board, 将于 202412月31 退休 (新闻发布的2024十月7号).
- David Wheadon已作为Director加入公司 (新闻发布的2024三月22号).
高管在Reckitt Benckiser变化
- Stefan OschmannStefan Oschmann 将于20251月1作为 Non-Executive Director 加入公司 (新闻发布的2024十一月27号).
- Mahesh MadhavanMahesh Madhavan 将于20251月1作为 Non-Executive Director 加入公司 (新闻发布的2024十一月27号).
- Alessio Fasano已作为Chief Science and Medical Officer, Mead Johnson Nutrition Business加入公司 (新闻发布的2024十一月26号).
创建提醒
跟踪 Indivior 的高管变动
药店
Reckitt Benckiser 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
Indivior 的最新新闻稿
- Indivior | Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
- Indivior | Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
- Indivior | Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
- Indivior | Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
- Indivior | Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
- Indivior | Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
- Indivior | Indivior Announces Q3 2024 Financial Results
- Indivior | Indivior Announces Q3 2024 Financial Results
- Indivior | Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
- Indivior | Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
- View more press releases Close
通过电子邮件
